Research programme: mRNA-based therapeutics - CytomX Therapeutics/Moderna
Alternative Names: mRNA encoded masked IL-12 - CytomX Therapeutics/Moderna; mRNA-based therapeutics; mRNA-based therapeutics - CytomX Therapeutics/ModernaLatest Information Update: 12 May 2026
At a glance
- Originator CytomX Therapeutics; Moderna Therapeutics
- Class Antineoplastics; RNA
- Mechanism of Action Interleukin 12 replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer